Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score.
I. Veiga Teijeiro (Lugo, Spain), I. Guzmán Peralta (Lugo, Spain), L. Pérez De Llano (Lugo, Spain), I. Martín Robles (Lugo, Spain), N. Blanco Cid (Lugo, Spain), D. Dacal Rivas (Lugo, Spain), I. Davila (Salamanca, Spain), E. Martínez-Moragón (Valencia, Spain), J. Domínguez Ortega (Madrid, Spain), C. Almonacid (Madrid, Spain), C. Colás (Zaragoza, Spain), J. García-Rivero (Laredo, Spain), L. Carmona (Santiago de Compostela, Spain), M. García De Yébenes (Madrid, Spain), B. García-Cosío (Palma de Mallorca, Spain)
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Veiga Teijeiro (Lugo, Spain), I. Guzmán Peralta (Lugo, Spain), L. Pérez De Llano (Lugo, Spain), I. Martín Robles (Lugo, Spain), N. Blanco Cid (Lugo, Spain), D. Dacal Rivas (Lugo, Spain), I. Davila (Salamanca, Spain), E. Martínez-Moragón (Valencia, Spain), J. Domínguez Ortega (Madrid, Spain), C. Almonacid (Madrid, Spain), C. Colás (Zaragoza, Spain), J. García-Rivero (Laredo, Spain), L. Carmona (Santiago de Compostela, Spain), M. García De Yébenes (Madrid, Spain), B. García-Cosío (Palma de Mallorca, Spain). Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score.. 1098
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
A new observer independent method to assess therapy response in children with severe asthma based on daily lung function Source: Annual Congress 2013 –Uncontrolled and severe asthma in children Year: 2013
Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Measuring inflammation inpaediatric severe asthma: biomarkers in clinical practice Source: Breathe, 16 (1) 190301; 10.1183/20734735.0301-2019 Year: 2020
Immunoproteasome function as a potential biomarker for asthma severity and response to therapy Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease Year: 2021
Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019 Year: 2019
Is sustained control of severe asthma possible? A composite score to assess 1-year of asthma control Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Development and evaluation of an educational intervention targeted at optimising adherence with measures to prevent asthma in children with a familial allergic disposition (FOCUS-project) Source: Eur Respir J 2002; 20: Suppl. 38, 329s Year: 2002
Quantitative analysis of severe asthma exacerbation requiring continuous inhalation therapy by measurements of modified pulmonary index score Source: Annual Congress 2013 –Uncontrolled and severe asthma in children Year: 2013
Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014
Identifying patients with severe asthma that will be benefit from biological therapy Source: Virtual Congress 2020 – Rethinking asthma Year: 2020
CompEx – A novel composite asthma exacerbation endpoint Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015
Study to evaluate clinical burden related with oral corticosteroids treatment of severe asthma in Spain (LEVANTE) Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020
Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies Year: 2009
TH 2 specific biomarker profile determines steroid responsiveness in severe asthma Source: Annual Congress 2013 –Biomarkers in asthma and COPD Year: 2013
Comparative assessment of the qol specific parameters in children with bronchial asthma with standard pharmacotherapy, and in additional course of physiotherapy in the pool Source: International Congress 2018 – Pulmonary rehabilitation: exercise training, body composition, physical activity and other aspects Year: 2018
Positive bronchodilator response is a poor predictor of future risk in well controlled asthma patients Source: International Congress 2016 – Functional assessment of the airways Year: 2016
Does clinical score evaluation improve management in bronchiolitis patients? Source: Eur Respir J 2007; 30: Suppl. 51, 391s Year: 2007
Clinical utility of impulse oscillation system (IOS) for the assessment of clinical status and therapeutic efficacy in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 421s Year: 2006
Grading of recommendations assessment, development and evaluation (GRADE) applied to severe asthma: evaluation and therapy Source: Annual Congress 2013 –ERS/ATS Task Force report on severe asthma Year: 2013
COPD related fatigue (COPD-RF) as a patient centred outcome tool in COPD: Various predictors and its correlation with other outcome parameters Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016